Lykos Therapeutics founder Rick Doblin recently went on the Joe Rogan experience to discuss the future of MDMA assisted therapy after the FDA's 2024 rejection. In the episode, he mentions that Lykos is currently renegotiating with Trump's new FDA regime in hopes of a reversal of last year's rejection. If this approach fails, Lykos will likely have to redo their Phase 3 studies which will set approval back by at least 3 years.
Stay up to date on Human 3 - the new epoch of health, wellbeing and performance